Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation.

[1]  G. de Sousa,et al.  Interspecies variability in mitoxantrone metabolism using primary cultures of hepatocytes isolated from rat, rabbit and humans. , 1991, Biochemical pharmacology.

[2]  A Iliadis,et al.  Population pharmacokinetics of mitoxantrone performed by a NONMEM method. , 1989, Journal of pharmaceutical sciences.

[3]  P. Arnoux,et al.  Direct determination of mitoxantrone and its mono- and dicarboxylic metabolites in plasma and urine by high-performance liquid chromatography. , 1988, Journal of chromatography.

[4]  S. Tanneberger,et al.  Mitoxantrone: mechanism of action, antitumor activity, pharmacokinetics, efficacy in the treatment of solid tumors and lymphomas, and toxicity. , 1987, Anticancer research.

[5]  R. M. Green,et al.  Human autopsy tissue concentrations of mitoxantrone. , 1986, Cancer treatment reports.

[6]  G. Fountzilas,et al.  Comparison of mitoxantrone and ametantrone in human acute myelocytic leukemia cells in culture and in bone marrow granulocyte-macrophage progenitor cells. , 1986, Cancer drug delivery.

[7]  T. Robak,et al.  [Clinical pharmacology of mitoxantrone]. , 1985, Polski tygodnik lekarski.

[8]  D. Alberts,et al.  Disposition of mitoxantrone in cancer patients. , 1985, Cancer research.

[9]  G. Ehninger,et al.  Detection and separation of mitoxantrone and its metabolites in plasma and urine by high-performance liquid chromatography. , 1985, Journal of chromatography.

[10]  C. Harvengt,et al.  Plasma kinetics of mitoxantrone in leukemic patients , 1984, Medical oncology and tumor pharmacotherapy.

[11]  D. Alberts,et al.  Disposition of mitoxantrone in patients. , 1983, Cancer treatment reviews.

[12]  I. Smith,et al.  Mitoxantrone (novantrone): a review of experimental and early clinical studies. , 1983, Cancer treatment reviews.

[13]  R. Benjamin,et al.  Clinical kinetics of 1,4‐dihydroxy‐5,8‐bis [[2‐ [(2‐hydroxyethyl)amino]ethyl] amino]‐9,10‐anthracenedione , 1982, Clinical pharmacology and therapeutics.

[14]  T. F. Patton,et al.  Plasma levels of 1,4-dihydroxy-5,8-bis ({2-[(2--hydroxylethyl)amino]ethyl}amino)-9,10-anthracenedione dihydrochloride (DHAD) in humans , 1981 .